Pharmacokinetics and Toxicity of Sodium Selenite in the Treatment of Patients with Carcinoma in a Phase I Clinical Trial: The SECAR Study

Pharmacokinetics and Toxicity of Sodium Selenite in the Treatment of Patients with Carcinoma in a Phase I Clinical Trial: The SECAR Study

Background: Sodium selenite at high dose exerts antitumor effects and increases efficacy of cytostatic drugs in multiple preclinical malignancy models. We assessed the safety and efficacy of intravenous administered sodium selenite in cancer patients’ refractory to cytostatic drugs in a phase I tria...

Full description

Bibliographic Details
Main Authors: Ola Brodin, Staffan Eksborg, Marita Wallenberg, Charlotte Asker-Hagelberg, Erik H. Larsen, Dag Mohlkert, Clara Lenneby-Helleday, Hans Jacobsson, Stig Linder, Sougat Misra, Mikael Björnstedt
Format: Article
Language:English
Published: MDPI AG 2015-06-01
Series:Nutrients
Subjects:
sodium selenite
carcinoma
pharmacokinetics
maximum tolerated dose
Online Access:http://www.mdpi.com/2072-6643/7/6/4978

Internet

http://www.mdpi.com/2072-6643/7/6/4978

Similar Items